Mesoblast Limited (MESO) Stock Price Today
Aura AI Summary
Key Stats
- $1.87BMarket Cap
- -Volume
- TechnologySector
- $20.9652W High
- $10.9652W Low
- -Typical Hold Time
- $1.88BEnterprise Value
- -Div Yield
- -Trading Activity
Track Mesoblast Limited (MESO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Mesoblast Limited has traded between a low of $10.96 and a high of $20.96, highlighting its annual price range. Buy and sell Mesoblast Limited shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Most Recent News
Document AI market to nearly double to $27.62B by 2030, driven by AI and automation in regulated industries.
The Document AI market is forecasted to grow from $14.66 billion in 2025 to $27.62 billion by 2030, at a CAGR of 13.5%. This growth is fueled by organizations adopting AI technologies like intelligent document processing, generative AI, and workflow ...

AI in orthopedic surgery market to hit $0.87B by 2030 with 27.2% CAGR, driven by tech advances and rising musculoskeletal disorders
The AI in orthopedic surgery market is projected to grow from $0.26 billion in 2025 to $0.87 billion by 2030, at a CAGR of 27.2%. Growth is fueled by increased orthopedic surgeries, innovations in medical imaging, adoption of minimally invasive techn...

Generative AI in drug discovery market to reach $0.86B by 2030, growing at 27% CAGR driven by faster drug development and AI advances
The generative AI market in drug discovery is expanding rapidly, expected to grow from $0.33 billion in 2026 to $0.86 billion by 2030 with a 27% CAGR. Growth is fueled by rising drug development costs, advances in AI technologies like deep learning, ...
